Poor
Not Aligned
Patient Risk:
High
Summary
The response is only partially supported by the provided label content. While the mechanism of action claim regarding DHFR inhibition is supported (12.1), multiple pharmacogenomic/genotype-outcome and pharmacogenetic testing/dose-adjustment claims are not supported by the supplied sections and therefore substantially reduce label alignment.
Category Scores
Accurate Statements
Methotrexate works by inhibiting the enzyme dihydrofolate reductase (DHFR).
Supported by 12.1 Mechanism of Action: "Methotrexate inhibits dihydrofolic acid reductase."
Unsupported Statements
Methotrexate is a folate antagonist.
The provided 12.1 text describes inhibition of dihydrofolic acid reductase but does not use or support the specific term "folate antagonist."
Genetic variations in genes encoding DHFR and other enzymes involved in folate metabolism can affect methotrexate efficacy and toxicity.
No provided label section addresses genetic polymorphisms or pharmacogenetic effects on efficacy/toxicity.
Individuals with the DHFR C677T variant have reduced methotrexate efficacy and increased toxicity.
No provided label section discusses DHFR C677T or genotype-outcome relationships.
DHFR C677T is associated with reduced methotrexate efficacy and increased toxicity, including liver damage and bone marrow suppression.
The provided label section 2.6 lists hepatotoxicity and myelosuppression as adverse-reaction reasons for dose modifications, but it does not link these outcomes to DHFR C677T.
The MTHFR C677T variant affects methylenetetrahydrofolate reductase (MTHFR), which is involved in folate metabolism.
No provided label section discusses MTHFR C677T or folate-metabolism gene variants.
Individuals with the MTHFR C677T variant may require higher doses of methotrexate to achieve the same therapeutic effect.
No provided label section addresses MTHFR C677T or dosing adjustments based on such variants.
MTHFR C677T is linked to increased methotrexate toxicity, including liver damage and neurological symptoms.
The provided label section 2.6 includes hepatotoxicity and neurotoxicity as adverse reactions guiding withholding/discontinuation, but it does not link these to MTHFR C677T.
SLC19A1 encodes a folate transporter that plays a critical role in methotrexate uptake.
No provided label section mentions SLC19A1, folate transporters, or uptake via SLC19A1.
Variants in SLC19A1 have been associated with reduced methotrexate efficacy.
No provided label section discusses SLC19A1 variants or efficacy associations.
ABCC2 encodes a protein involved in the transport of methotrexate and its metabolites.
No provided label section mentions ABCC2 or transport of methotrexate/metabolites.
Variants in ABCC2 have been associated with increased methotrexate toxicity.
No provided label section discusses ABCC2 variants or genotype-associated toxicity.
Pharmacogenetic testing can help identify individuals who are more likely to benefit from methotrexate treatment.
No provided label section discusses pharmacogenetic testing for predicting benefit.
Pharmacogenetic testing can help identify individuals who may require dose adjustments to minimize methotrexate toxicity.
The provided label section 2.6 describes dose modifications based on adverse reactions, but it does not mention pharmacogenetic testing guiding dose adjustments.
Contradictions
Important Omissions
No label-grounded guidance (from the provided sections) was included regarding how dosing modifications should be managed (e.g., withholding/discontinuation criteria) beyond generic adverse-reaction mentions; instead, the response focuses on gene-based dosing/testing claims not present in the provided label sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response makes multiple gene-variant and pharmacogenetic testing claims that are not supported by the supplied label content, including claims implying genotype-guided dose adjustment and toxicity mitigation. While these do not directly instruct administration from the label, they can materially mislead dosing decisions relative to on-label guidance provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the response introduce pharmacogenomic/genotype-outcome and pharmacogenetic testing/dose adjustment claims that are absent from the provided FDA label sections.
Suggested Improvement
Restrict claims to on-label information present in the provided sections (e.g., methotrexate inhibits dihydrofolic acid reductase per 12.1 and dose modifications/withhold/discontinue criteria for adverse reactions per 2.6) and remove all specific variant/genotype-testing claims that are not supported by the provided label text.